Sakar Healthcare Ltd
NSE:SAKAR
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Sakar Healthcare Ltd
Operating Income
Sakar Healthcare Ltd
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
S
|
Sakar Healthcare Ltd
NSE:SAKAR
|
Operating Income
₹288m
|
CAGR 3-Years
14%
|
CAGR 5-Years
18%
|
CAGR 10-Years
18%
|
|
|
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
|
Operating Income
₹63.2B
|
CAGR 3-Years
10%
|
CAGR 5-Years
14%
|
CAGR 10-Years
10%
|
|
|
Cipla Ltd
NSE:CIPLA
|
Operating Income
₹53.3B
|
CAGR 3-Years
15%
|
CAGR 5-Years
12%
|
CAGR 10-Years
9%
|
|
|
Divi's Laboratories Ltd
NSE:DIVISLAB
|
Operating Income
₹29.4B
|
CAGR 3-Years
4%
|
CAGR 5-Years
5%
|
CAGR 10-Years
N/A
|
|
|
Lupin Ltd
NSE:LUPIN
|
Operating Income
₹59.6B
|
CAGR 3-Years
147%
|
CAGR 5-Years
32%
|
CAGR 10-Years
8%
|
|
|
T
|
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
|
Operating Income
₹33.6B
|
CAGR 3-Years
19%
|
CAGR 5-Years
13%
|
CAGR 10-Years
4%
|
|
Sakar Healthcare Ltd
Glance View
Sakar Healthcare Ltd. engages in the manufacture of pharmaceutical products. The company is headquartered in Ahmedabad, Gujarat. The company went IPO on 2016-10-14. The firm is engaged in the manufacturing of pharmaceutical products providing liquid orals, cephalosporin tablets, capsules, dry powder syrup, dry powder injections, liquid injectable (SVP) in ampoules, vials & lyophilized injections, oral solid dosages, and research & development of the above products. The Company’s products include Oral - Liquid Syrup & Suspension, Liquid Injectable (SVP)-Vials & Ampoules, Cephalosporin - Dry Powder Injections, Cephalosporin Oral Solid and Lyophilised Injections (In Vials). The firm operates as a contract manufacturer for multinational pharmaceutical companies. The firm serves various countries such as Southeast Asia, Asia, Africa-Anglo & Francophone, MENA, America, covering approximately 38 countries. The Company’s subsidiaries include Sakar Oncology Private Limited.
See Also
What is Sakar Healthcare Ltd's Operating Income?
Operating Income
288m
INR
Based on the financial report for Mar 31, 2025, Sakar Healthcare Ltd's Operating Income amounts to 288m INR.
What is Sakar Healthcare Ltd's Operating Income growth rate?
Operating Income CAGR 10Y
18%
Over the last year, the Operating Income growth was 42%. The average annual Operating Income growth rates for Sakar Healthcare Ltd have been 14% over the past three years , 18% over the past five years , and 18% over the past ten years .
